Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Neuland Laboratories is accelerating its peptide manufacturing expansion, as the first of four scheduled modules has commenced operations at its commercial peptide manufacturing site.
Significantly, with foundational infrastructure for the second module already in place, Neuland expects to begin work ahead of the original timeline once customer requirements are finalised — configuration, instrumentation and capacity are currently being defined in close collaboration with the customer whose projects will anchor the expanded capability.
The newly operational module one provides 7000L total reactor capacity, 750L of solid-phase peptide synthesis and 6250L liquid-phase peptide synthesis. This enables flexible customer programmes from small-scale to multikilogram quantities for complete peptide APIs – including complex and long-chain peptides – as well as commercial scale production of crude peptides. Additionally, the SPPS and LPPS reactors are housed in different suites enabling parallel operation and are supported by three DAC columns [one 45 cm and two 60 cm] and two lyophilisers with 100 L and 200 L capacities.
Following the $30 million investment in module one, Neuland is aligning further investment for subsequent modules with new customer requirements. Module two is planned to provide an overall reactor capacity of up to 18,000 L, comprising three 5,000 L LPPS reactors, as well as either a 1,000 L or 2,000 L SPPS reactor, and smaller reactors of up to the 1,000 L scale. This flexible configuration will allow Neuland to support a broad range of peptide programmes and production scales.
The range of partner indications is also broadening beyond obesity and metabolic disease, with oncology emerging as a particularly active area of early-stage development. As peptide pipelines expand, a growing number of biotech companies are struggling to access capable outsourced development and commercial manufacturing capacity.
Net sales more than doubled, rising 119.16% YoY to Rs 641.58 crore, reflecting strong business momentum during the quarter.
Profit before tax (PBT) surged to Rs 197.84 crore in Q1 FY27, up 1,026.01% compared with Rs 17.57 crore in the year-ago period.
Operating performance strengthened significantly, with EBITDA jumping 448.2% YoY to Rs 231.1 crore from Rs 42.1 crore in Q1 FY26. EBITDA margin expanded by 1,250 basis points to 35.5%, compared with 14% in the corresponding quarter last year, supported by improved operating leverage and a favourable product mix.
Saharsh Davuluri, chief executive officer and managing director, Neuland Laboratories added “Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS businesses and represents a good start to the year. While Commercial Products contributed to most of the revenue, we are seeing exciting developments in terms of the pipeline projects.
The depth of customer conversations today is significantly stronger, and we are increasingly engaging on broader capability-led discussions rather than individual projects alone. Internally our focus now is on ensuring that we deliver consistently, build customer confidence and establish the foundation for longterm partnerships. Even as we have invested significantly over the last three years and all our significant capex projects are proceeding according to plan, I believe the intensity of our investments will further increase based on the opportunities that available to us.”
Meanwhile, Neuland Laboratories and Gland Pharma have entered into a long-term strategic contract development and manufacturing organization (CDMO) partnership to address the growing global demand for sterile active pharmaceutical ingredients (APIs) used in microparticle depot products and other complex sterile APIs. As part of the collaboration, Gland Pharma will establish a dedicated sterile manufacturing suite for these products, combining Neuland's expertise in complex API development, process chemistry and custom manufacturing with Gland Pharma's sterile manufacturing capabilities and strong regulatory compliance track record.
In connection with the partnership, Neuland Laboratories' board has approved the execution of a corporate guarantee of Rs 40 crore in favour of Gland Pharma to support the company's obligations under a proposed Loan Licence Agreement. The agreement will facilitate the establishment of the dedicated manufacturing facility and the associated capital expenditure for producing the specified products.
Additionally, the company's board approved the expansion of manufacturing capacity at Unit 1 in Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. The facility is currently operating at 91% capacity utilisation, with an installed capacity of 276.5 kiloliters (KL). The company plans to add 18 KL of capacity through an investment of Rs 39.8 crore to meet growing customer demand.
Neuland Laboratories is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions to customers in approximately 80 countries.
Neuland Laboratories Ltd, GMM Pfaudler Ltd, Shaily Engineering Plastics Ltd and Hindustan Aeronautics Ltd are among the other gainers in the BSE's 'A' group today, 06 August 2026.
Navin Fluorine International Ltd spiked 10.77% to Rs 8420 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 1.46 lakh shares were traded on the counter so far as against the average daily volumes of 11408 shares in the past one month.
Neuland Laboratories Ltd surged 9.96% to Rs 21954.1. The stock was the second biggest gainer in 'A' group. On the BSE, 38160 shares were traded on the counter so far as against the average daily volumes of 2533 shares in the past one month.
GMM Pfaudler Ltd soared 7.31% to Rs 919.85. The stock was the third biggest gainer in 'A' group. On the BSE, 39874 shares were traded on the counter so far as against the average daily volumes of 9273 shares in the past one month.
Shaily Engineering Plastics Ltd added 7.17% to Rs 3400. The stock was the fourth biggest gainer in 'A' group. On the BSE, 50592 shares were traded on the counter so far as against the average daily volumes of 27255 shares in the past one month.
Hindustan Aeronautics Ltd jumped 6.03% to Rs 4895. The stock was the fifth biggest gainer in 'A' group. On the BSE, 2.41 lakh shares were traded on the counter so far as against the average daily volumes of 49350 shares in the past one month.
Clean Science & Technology Ltd, Neuland Laboratories Ltd, Cummins India Ltd, Navin Fluorine International Ltd are among the other stocks to see a surge in volumes on BSE today, 06 August 2026.
JK Lakshmi Cement Ltd recorded volume of 2.11 lakh shares by 10:46 IST on BSE, a 41.43 times surge over two-week average daily volume of 5081 shares. The stock gained 4.61% to Rs.597.70. Volumes stood at 5117 shares in the last session.
Clean Science & Technology Ltd saw volume of 8.09 lakh shares by 10:46 IST on BSE, a 10.32 fold spurt over two-week average daily volume of 78345 shares. The stock dropped 0.41% to Rs.766.00. Volumes stood at 41016 shares in the last session.
Neuland Laboratories Ltd saw volume of 28393 shares by 10:46 IST on BSE, a 9.76 fold spurt over two-week average daily volume of 2908 shares. The stock increased 8.14% to Rs.21,589.00. Volumes stood at 2844 shares in the last session.
Cummins India Ltd registered volume of 90164 shares by 10:46 IST on BSE, a 8.74 fold spurt over two-week average daily volume of 10320 shares. The stock rose 0.30% to Rs.5,424.40. Volumes stood at 16702 shares in the last session.
Navin Fluorine International Ltd witnessed volume of 1.03 lakh shares by 10:46 IST on BSE, a 5.61 times surge over two-week average daily volume of 18445 shares. The stock increased 6.44% to Rs.8,090.55. Volumes stood at 6113 shares in the last session.
Neuland Laboratories Ltd, Cohance Lifesciences Ltd, Authum Investment & Infrastructure Ltd, Tata Technologies Ltd are among the other stocks to see a surge in volumes on NSE today, 06 August 2026.
Navin Fluorine International Ltd clocked volume of 29.35 lakh shares by 14:14 IST on NSE, a 21.8 times surge over two-week average daily volume of 1.35 lakh shares. The stock gained 12.73% to Rs.8,578.00. Volumes stood at 1.37 lakh shares in the last session.
Neuland Laboratories Ltd saw volume of 8.36 lakh shares by 14:14 IST on NSE, a 21.66 fold spurt over two-week average daily volume of 38596 shares. The stock increased 7.83% to Rs.21,518.00. Volumes stood at 60067 shares in the last session.
Cohance Lifesciences Ltd saw volume of 49.61 lakh shares by 14:14 IST on NSE, a 17.51 fold spurt over two-week average daily volume of 2.83 lakh shares. The stock increased 2.65% to Rs.440.85. Volumes stood at 3.66 lakh shares in the last session.
Authum Investment & Infrastructure Ltd registered volume of 21.81 lakh shares by 14:14 IST on NSE, a 9.97 fold spurt over two-week average daily volume of 2.19 lakh shares. The stock rose 4.53% to Rs.596.35. Volumes stood at 2.89 lakh shares in the last session.
Tata Technologies Ltd recorded volume of 72.03 lakh shares by 14:14 IST on NSE, a 7.81 times surge over two-week average daily volume of 9.23 lakh shares. The stock gained 5.79% to Rs.797.65. Volumes stood at 3.35 lakh shares in the last session.
Gland Pharma and Neuland Laboratories today announced a long-term strategic CDMO partnership.
Under the partnership Gland will establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products. The collaboration combines Neuland's Complex API development and manufacturing capabilities including deep expertise in complex chemistry, process development, custom manufacturing having a strong track record of serving global innovator and generic pharmaceutical companies; with Gland Pharma's global sterile manufacturing expertise and strong regulatory compliance track record, to serve growing worldwide demand for sterile APIs used in microparticle depot products and other complex sterile APIs.
Under the collaboration, Gland Pharma will expand its existing sterile manufacturing infrastructure through an additional dedicated suite at its JNPC facility at Visakhapatnam to support Neuland for its growing demand of sterile APIs. The facility will be constructed and operated to cGMP, USFDA and EU standards, and will be backed by Gland Pharma's proven aseptic manufacturing expertise. Together, the companies will offer an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs. The suite will be designed to add approximately 1400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth.
Existing capacity - 256 KL Existing capacity utilization - 91% Proposed capacity addition - 120.5 KL Period for capacity addition - within 12-18 months Investment required - Rs 143.4 crore (funded through internal accruals and borrowings)